Compare Neurocrine Biosciences Inc (NBIX) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Global X Uranium ETF — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Global X Uranium ETF trades at $38.9 (market cap $5.48B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.6× Global X Uranium ETF's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Global X Uranium ETF for 62 Days on average.
| NBIX | URA | |
|---|---|---|
Market Cap | $14.36B | $5.48B |
Volume | 1,237,180 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $185.50 | $61.81 |
52-Week Low | $123.10 | $37.52 |
Typical Hold Time | 23 Days | 62 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
URA, the Global X Uranium ETF, trades at $38.56, down 3.43% in the last session amid a bearish technical signal. Key support lies at $37, with resistance at $39. The fund provides exposure to uranium miners and nuclear energy companies, benefiting from structural supply deficits and rising demand for reliable power, particularly from AI data centers. Recent index additions like Terra Innovatum and Eagle Nuclear Energy reflect ongoing sector expansion.
The outlook for URA is mixed; long-term demand drivers from nuclear energy adoption and AI power needs are strong, but near-term price volatility and concentrated holdings pose risks. Investors should weigh the sector's growth potential against ETF-specific fluctuations and broader market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
